Minerva anestesiologica
-
Minerva anestesiologica · Mar 2015
Observational StudyPrediction of haemodynamic reactivity during total intravenous anaesthesia for suspension laryngoscopy using Analgesia/Nociception Index (ANI): a prospective observational study.
The Analgesia/Nociception Index (ANI), a 0-100 non-invasive index calculated from heart rate variability, reflects the analgesia/nociception balance during general anesthesia. The principal objective of this study was to evaluate the performance of ANI to predict hemodynamic reactivity during suspension laryngoscopy. The secondary objectives were to investigate the performances of ANI and bispectral index (BIS) to assess sedation and of BIS to predict hemodynamic reactivity during the procedure. ⋯ ANI exhibits good performance for the prediction of hemodynamic reactivity and BIS exhibits good performance for the assessment of sedation during suspension laryngoscopy with propofol/remifentanil total intravenous anesthesia.
-
Minerva anestesiologica · Mar 2015
No correlation between remifentanil blood, Cerebro-spinal fluid and cerebral extracellular fluid levels and TCI prediction: a pharmacokinetic study.
The aims of this paper were to elucidate the difference in concentration among remifentanil blood, cerebrospinal fluid and cerebral extracellular fluid levels, and to verify the presumable existence of a correlation between arterial and cerebral remifentanil. We used brain microdialysis to shed light on this aspect of the pharmacokinetic and to correlate these findings with Minto's model. ⋯ There was a wide interindividual variability with regard both to blood and cerebral remifentanil concentration. Moreover, the ratio between arterial blood and cerebral remifentanil was not consistent among our patients in spite of a stable infusion rate of remifentanil; at the end we found a trend of over prediction in the ratio between the various compartments examined.
-
Minerva anestesiologica · Mar 2015
Editorial CommentEvery need is perfectly met if you do not measure it.
-
Minerva anestesiologica · Feb 2015
ReviewMesenchymal Stromal cell therapies - potential and pitfalls for ARDS.
Mesenchymal stem/stromal cells (MSCs) offer considerable promise as a novel therapeutic strategy for acute respiratory distress syndrome (ARDS). MSCs may be able to "reprogramme" the immune response to reduce destructive inflammatory elements while preserving the host response to pathogens. In addition, MSCs may be able to enhance the repair and resolution of lung injury. ⋯ The fact that MSCs are in clinical studies for a wide range of disease processes is a clear advantage for translating MSCs to clinical testing in patients with ARDS. However, some important knowledge gaps exist that may impede clinical translation. The ultimate success of MSCs as a therapy for patients with ARDS will likely be dependent on a greater knowledge of their mechanisms of action and the determination of the optimal strategies for their use in the clinical setting.